	US 12,458,612 B2
	Combination therapy comprising compounds of formula (I) and GLP-1 receptor agonists
Robert Walczak, Lille (FR); Vanessa Legry, Emmerin (FR); and Emeline Descamps, Gondecourt (FR)
Assigned to GENFIT, Loos (FR)
Appl. No. 17/602,296
Filed by GENFIT, Loos (FR)
PCT Filed Apr. 9, 2020, PCT No. PCT/EP2020/060283 § 371(c)(1), (2) Date Oct. 8, 2021, PCT Pub. No. WO2020/208205, PCT Pub. Date Oct. 15, 2020.
Claims priority of application No. 19305468 (EP), filed on Apr. 10, 2019.
Prior Publication US 2022/0362187 A1, Nov. 17, 2022
Int. Cl. A61K 31/192 (2006.01); A61K 38/26 (2006.01); A61P 1/16 (2006.01); A61P 3/10 (2006.01)

CPC A61K 31/192 (2013.01) [A61K 38/26 (2013.01); A61P 1/16 (2018.01); A61P 3/10 (2018.01)]

15 Claims

1. A method for treating a condition for which the administration of a GLP-1 receptor agonist is needed comprising the administration of a combination product to a subject in need thereof,

wherein the condition is selected from the group consisting of non-alcoholic fatty liver disease, diabetes and obesity,

and wherein the combination product comprises:

(i) elafibranor or a pharmaceutically acceptable salt thereof; and

(ii) a Glucagon-like peptide-1 (GLP-1) receptor agonist selected from the group consisting of semaglutide, liraglutide and a pharmaceutically acceptable salt thereof,

wherein the amount of Glucagon-like peptide-1 (GLP-1) receptor agonist that is administered is reduced at least 1.5-fold as compared to the amount of GLP-1 agonist required when administered alone.